Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for treatment of embolic stroke of undetermined source
2014-005109-19Phase 3Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban in embolic stroke of undetermined source (ESUS), ischemic stroke and brain hemorrhage (ICH) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Primary composite endpoint. Started Jun 2015; status: terminated.
02
Drugs
apixaban
03
Conditions
embolic stroke of undetermined source (ESUS)ischemic strokebrain hemorrhage (ICH)
Beyond the preview
Go deeper on 2014-005109-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005109-19.